Introduction Feverfew (Tanacetum parthenium) is a medicinal herb commonly used in self treatment for conditions such as migraine and arthritis. In one survey more than 70%, of 270 migraine sufferers who had eaten feverfew leaves every day for prolonged periods claimed that the herb decreased the frequency of the attacks or caused them to be less painful, or both.' Many of these people had failed to respond to orthodox medicines. Although possible mechanisms of action have been proposed for the beneficial effects of feverfew,' 4 no one appears to have questioned whether it is in fact clinically effective in any condition.
From a large number of migraine sufferers known to the City of London Migraine Clinic to be treating themselves with feverfew 20 were invited to enter a double blind study, aware only that they might be treated with either active dried feverfew or placebo.
Patients and methods
We aimed to recruit 20 patients who had been treating themselves with raw feverfew leaves every day for at least three months. Ten patients were to receive active treatment consisting of freeze dried, powdered feverfew leaves in capsule form and 10 placebo. The patients had to have a history of common or classical migraine of at least two years' duration with no more than eight attacks a month at the time of admission.
We had intended to exclude patients who had taken the following drugs within one month of the study: tranquillisers, a blockers, ,B blockers, antidepressants, non-steroidal anti-inflammatory agents, or clonidine and pitzotifen used prophylactically. In the event we decided that this criterion could be waived if patients had begun prophylactic treatment with one of these drugs before starting to use feverfew daily, and provided that those taking antidepressants or tranquillisers showed no signs of current mental illness.
Before admission the nature and purpose of the study, including possible benefits and problems, were explained to each patient by one of us (ESJ), and the patient's informed consent to participate was obtained. Three patients refused to participate because they feared the possible consequences of being assigned to the group receiving placebo. The study was approved by the ethical committee of the City and Hackney District Health Authority.
Trial design-The trial was a double blind, placebo controlled comparison between two groups. Successive patients who had suffered from classical or common migraine for at least two years were allocated randomly to receive either feverfew or identical placebo capsules in numbered packs. Patients and production of the capsules at Chelsea College was approved by the Department of Health and Social Security. The contents of the placebo capsules were matched for colour with the active capsules with chlorophyll. The feverfew used was grown in the Chelsea Physic Garden and harvested in a single batch in September. The contents of the bottles were sprinkled with a small amount (1-2 mg) of feverfew powder so that on opening both active and placebo capsules gave identical smells.
Safety tests-Patients were asked to donate sufficient venous blood for routine analysis of its cellular and chemical elements and to provide a sample of urine for routine analysis (pH; excretion of bilirubin, blood, and glucose; and sediment).
Statistical analysis-Non-parametric statistical methods such as the Wilcoxon rank sum test were used for comparisons between the treatments and the Wilcoxon matched pairs signed ranks test for comparisons within the groups of frequencies of headache, nausea, vomiting, global assessment of efficacy, and correct detection by patients of the treatment that they were receiving. Parametric t tests were used as appropriate for quantitative measurements such as blood pressure, heart rate, and weight.
Results
Characteristics of patients on admission-Eight patients (mean age 44-9 (SEM 4-2) years) received feverfew and nine (mean age 51-2 (2 3) years) received placebo capsules. The patients in the active group had taken 2 44 (0-2) small leaves of feverfew daily for 3-38 (0 58) years before entry to the study, and those in the placebo group had taken 2-33 (0 48) small leaves daily for 4 18 (0 67) years. Thus the two groups did not differ in the amount of feverfew consumed daily or the duration of consumption. The two groups also did not differ significantly in their recollection of the frequency of migraine before self treatment with feverfew (t test or Wilcoxon's rank sum test, 0 1 > p >0 05). Patients in the active group claimed that they had suffered 7 44 (1 33) attacks each month before self treatment with feverfew and that during self treatment the monthly rate had fallen to 1-63 (0 73) attacks (table I), whereas those in the placebo group had suffered only 3-94 (1 08) attacks each month before self treatment with feverfew and 1-22 (0-54) during self treatment. The reduction in the frequency of migraine during self treatment was significant for both groups (Wilcoxon's matched pairs signed rank test: feverfew group p < 0-05, placebo group p < 0-01). Thus when the two groups were recruited to the study their mean numbers of attacks each month were similar.
Concomitant drugs taken throughout the study-One patient in each group was taking conjugated equine oestrogens (Premarin); the patient in the placebo group was also taking pizotifen. One patient given feverfew was taking the combined oral contraceptive Orlest 21.
One patient in each group was taking a diuretic: the patient given fever- Comparative data are given for the whole six months and also for the final three months to exclude any carryover effects in the placebo group during the initial months of the study. The patients taking feverfew experienced 1 5 (0-62) attacks a month during the final three months (1-69 (0 57) over the six months), which was identical with the frequency of attacks when they were taking raw leaves. On the other hand, the frequency in patients taking placebo increased to (1-02) attacks a month in the final three months (3-13 (0 77) over the six months), which was significantly higher than the frequency when these patients were taking raw feverfew leaves (p < 0 02). In fact, the frequency of headaches in the patients taking placebo was almost identical with that reported by these patients before they began self treatment with feverfew leaves.
Guessing of treatment received-Patients were asked to guess each month which of the two treatments they were receiving. Table II shows that most patients consistently guessed correctly.
Incidence and severity of nausea and vomiting- Discontinuation of feverfew-The abrupt discontinuation of consumption of feverfew after several years' use led to the recurrence of incapacitating migraine in some patients. Two women (cases 14 and 16), whose migraine was in complete remission during self treatment with feverfew leaves, could not bear to complete the study and withdrew from it to resume consumption of raw feverfew. The patient in case 14 (figure) had had no attacks while taking two or three small leaves of feverfew (roughly 75 mg dried powder) daily for four and a half years. When the feverfew was replaced by placebo for six weeks she suffered severe migraine, which stopped only when she withdrew from the trial and resumed self treatment. Six weeks later she again agreed to take the capsules, whose contents remained unknown to her. The recurrence of extremely severe migraine caused her to withdraw from the study again and revert to her daily regimen. She had no attacks of migraine in the subsequent six months. The patient in case 16 had had no attacks during the six months before entering the study. She had had an average of two or three attacks a year during the four years in which she consumed one small leaf (roughly 25 mg dried powder) daily. While taking placebo she had her first attack after 13 days, but when she resumed self treatment with the leaves attacks gradually decreased in severity before disappearing completely. The slower rate of decrease in severity experienced by this patient when she resumed treatment with feverfew compared with that in case 14 probably reflects the fact that the patient in case 14 was taking three times the "dose" of this patient. Eight months after the study she was still free of migraine while consuming feverfew equivalent to only 5 mg dried powder daily. Effects of feverfew on the cardiovascular system-Before treatment the mean blood pressure (sitting) in the patients in the feverfew group was 134/86 mm Hg; after six months of treatment it was 125/ 82 mm Hg. The corresponding values in those in the placebo group were 122/80 mm Hg and 120/82 mm Hg. Although the two groups differed significantly in their systolic blood pressures before treatment, there were no significant differences between them after six months of treatment. This is particularly important in the group taking placebo, in which both systolic and diastolic blood pressures were almost identical before and at the end of treatment. There were no significant changes within the groups (paired t test). Although heart rates before treatment were similar in the two groups, the heart rates in the group given feverfew were significantly higher (p < 0 05) at the end of treatment, a result accounted for by two patients (cases 4 and 5) whose heart rates were 26 and 20 beats higher at the end of treatment.
Effect offeverfew on body weight-Mean body weights did not change significantly throughout the six months of the study, with a mean decrease of 0-6 kg in the group given feverfew compared with an increase of 0-2 kg in the placebo group.
Adverse events-All patients taking placebo reported at least one event (table VI), whereas four patients taking feverfew reported none. The events in the placebo group were related to the central nervous and musculoskeletal systems and included feelings of nervousness, tension, tension headaches, insomnia or disturbed sleep, and tiredness.
Three of these patients also experienced pain or stiffness in the joints. These symptoms were particularly serious during the first two months of placebo treatment but lessened subsequently. None of these symptoms were experienced by patients taking feverfew. The two patients taking feverfew who complained of stiffness in the joints had suffered this throughout their self treatment with raw leaves. Results of laboratory tests-Blood was taken for full haematological and biochemical analysis on enrolment and at the end of the trial. Complete data were obtained for eight patients in each group. No blood was taken from one patient (case 16) during treatment with placebo as she withdrew after the third month and was again taking feverfew by the time of her subsequent visit to the clinic. The blood obtained in case 14 was taken at the end of period 4, just before the patient withdrew from the study for the second time. There were no differences within or between the groups in the incidence of abnormal laboratory findings or in changes of values from normal to abnormal and vice versa.
Discussion
In recent years, after newspaper reports of successful responses in sufferers resistant to conventional treatments, patients with migraine and arthritis have turned to the herb feverfew.1 6 Although most users eat fresh leaves, the health food industry has responded rapidly to the demand for tablets and capsules containing dried feverfew. The development of most of the available tablets and capsules has not, however, been based on clinical observation or clinical trials, and several "high dose" products have been introduced, which contain up to four times the amount of feverfew that has been taken daily by most users.
Analysis of detailed questionnaires completed by some 300 users yielded considerable information about migraine sufferers who turn to feverfew.1 5 The mean frequency of attacks of migraine in those who were given placebo increased from the low level of 1-22 attacks each month during self treatment to three times this number, which was the number suffered before self treatment. Those who took capsules containing powdered feverfew showed no change in the frequency of their attacks. Two people taking placebo capsules withdrew from the study to resume use of raw feverfew leaves. The severe attacks of migraine that they suffered while taking the placebo were prevented when they resumed treatment with the leaves.
Far fewer severe and incapacitating headaches were recorded by the patients taking feverfew than by those taking placebo. The patients taking feverfew also suffered a far lower incidence of nausea and vomiting (39 reports compared with 116 in the placebo group). Furthermore, only 42% of attacks of migraine recorded by patients taking feverfew were associated with these symptoms compared with 79% of those experienced by patients taking placebo.
The global assessment made by patients at the end of the trial showed that significantly more patients given feverfew thought that they had benefited from treatment. Dried feverfew capsules did not appear to affect blood pressure, heart rate, body weight, or the results of haematological and biochemical tests, but there was one report each of transient palpitations, colicky abdominal pain, and heavier menstruation. Stiffness in the joints was reported by two patients taking feverfew but was not considered to be due to treatment as the patients had had the condition before starting self treatment.
The distribution of adverse events differed greatly between the two groups. All patients given placebo reported at least one event. There were five reports of increased nervousness, three of tension headaches, two of insomnia or disturbed sleep, and three of stiffness in the joints. We believe that these effects constitute a genuine "postfeverfew syndrome" as when 164 users who had stopped taking feverfew were asked to describe their symptoms about one tenth complained of moderate to severe aches, pains, and stiffness in joints and muscles together with central nervous system symptoms of anxiety and poor sleep.5
The users of feverfew who were admitted to this study had tolerated the daily intake of leaves well and complained only of the herb's disagreeable flavour. showed no important abnormalities before treatment with the capsules was begun and no differences between the two groups at the end of the six months of study. The fact remains, however, that no studies of chronic toxicity have yet been performed on the plant. Indeed, it could be argued that the usual toxicity tests in animals lasting six months are now superfluous because feverfew has been used by large numbers of people continuously for many years (more than 10 years in some cases). Given the variation in sesquiterpene lactone content between varieties of feverfew and plants harvested in different seasons (P J Hylands, unpublished findings), it would seem desirable for commercial preparations of feverfew to be standardised chemically.
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REPORTS
Plasminogen activator inhibitor in the blood of patients with coronary artery disease Impairment of fibrinolytic activity in blood has been claimed to contribute to the development of coronary artery disease and myocardial infarction.1 Human plasma contains a fast acting inhibitor of tissue type plasminogen activator, which may have a primary role in the regulation of the fibrinolytic system.2 Increased activity of this plasminogen activator inhibitor has been found in clinical and experimental conditions associated with reduced fibrinolytic activity and thrombotic phenomena.3 4We studied the activity of plasminogen activator inhibitor in the plasma of patients with angiographic evidence of coronary artery disease.
Patients, methods, and results
We studied 118 patients (92 men and 26 women, aged 35-70) with angina pectoris who were admitted for coronary angiography and in whom stenosis of the coronary artery was documented. Coronary angiograms were evaluated using a computer assisted reporting system.5 An overall score of the severity of the coronary lesions was calculated, which took into account the graded narrowing, length, number, and site of the different stenoses. On the basis of this evaluation three patient groups were distinguished: patients with slight coronary lesions (coronary severity score < 25; n= 45); patients with moderate lesions (coronary severity score 26-50; n= 50); and patients with severe lesions (coronary severity score >50; n=23). Twenty six patients were taking a adrenergic blockers at the time of angiographic evaluation. Blood samples were collected on trisodium citrate (O0Ol lM final concentration) on arrival at the hospital. Plasma was immediately prepared by centrifugation (20 minutes at 1500 g) and stored at -70°C. A control group matched for age consisting of 57 apparently healthy subjects (31 men and 26 women, aged 40-64) was studied simultaneously. Plasma euglobulin fibrinolytic activity was measured with the fibrin plate method, tissue type plasminogen activator related antigen by a two site immunoradiometric assay, and activity of plasminogen activator inhibitor with an amidolytic assay. 4 Significantly increased activity of plasminogen activator inhibitor (3-1 (SD 1-2) U/ml v 1-5 (0 7) U/ml, p< 0 001) and concentrations of tissue type plasminogen activator antigen (10-6 (3-7) ng/ml v 6-4 (3-1) ng/ml, p < 0-001) were found in the patients compared with the controls (figure); plasma euglobulin fibrinolytic activity was, however, not significantly different (0-8 (0 3) IU/ml v 0 9 (0-2) IU/ml). The activity of plasminogen activator inhibitor and concentration of tissue type plasminogen activator antigen were not significantly different in the three groups of patients with different degrees of coronary lesions.
No correlation was found between plasma activity of plasminogen activator inhibitor and either the concentration of tissue type plasminogen activator antigen or the euglobulin fibrinolytic activity. Plasminogen activator inhibitor activity did not correlate with cholesterol and high density lipoprotein cholesterol concentrations and was not different in patients taking 5 adrenergic blockers. Finally, there was no difference related to sex in the plasminogen activator inhibitor activity or the concentration of tissue type plasminogen activator antigen either in the patients (3-0 (1-3) U/ml in men v 3-3 (1-2) U/ml in women, and 10-7 (3.8) ng/ml v 9-8 (3-2) ng/ml) or in the controls (1-5 (0 7) U/ml v 1-5 (0.7) U/mrl, and 7-0 (3-0) ng/ml v 6-0 (3-1) ng/ml). Activity of plasminogen activator inhibitor (left) and concentration of tissue type plasminogen activator antigen (right) in plasma of patients with coronary artery disease and controls. Means (and SD) are shown.
Comment
Our findings suggest that the fibrinolytic system is altered in patients with coronary artery disease. In particular, the functional levels of the fast acting inhibitor of plasminogen activator are significantly increased. The observations that the overall euglobulin fibrinolytic activity is similar in patients and controls and does not correlate with the plasma plasminogen activator inhibitor activity are not totally surprising. The euglobulin fraction, indeed, contains other plasminogen activators different from tissue type plasminogen activator (and not neutralised by plasminogen activator inhibitor), which may represent more than 90%/ of the total activity and, most probably, do not have an important role in the activation of the fibrinolytic system m vivo.
The increased activity of plasminogen activator inhibitor in the plasma of patients with coronary artery disease may contribute to the impairment of the fibrinolytice capacity and thus represent another risk factor worthy of consideration in the disease. 
